Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsPediatric Oncology and HematologyProtocol groupHematologic Diseases (ped.)Histiocytic and Dendritic NeoplasmsDiseaseLangerhans Cell HistiocytosisSubgroupBRAF V600-MutationICD10C96.0C96.5C96.6MeSHErdheim-Chester DiseaseHistiocytosis, Langerhans-CellHistiocytosis, SinusSequenceVNBL6/PRED(20/10), LCH, Ind. (PID963) -|- maint. (PID959)ChemotherapyChemo-substanceCladribineCobimetinibCytarabineHydroxyureaMethotrexatePrednisoloneVemurafenibVinblastineChemo-substanceCladribineCobimetinibCytarabineHydroxyureaMethotrexatePrednisoloneVemurafenibVinblastineChemo-substanceCladribineCobimetinibCytarabineHydroxyureaMethotrexatePrednisoloneVemurafenibVinblastineChemo-substanceCladribineCobimetinibCytarabineHydroxyureaMethotrexatePrednisoloneVemurafenibVinblastineNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%Folinic acidFurosemideGranisetronNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%Folinic acidFurosemideGranisetronNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%Folinic acidFurosemideGranisetronNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%Folinic acidFurosemideGranisetronNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateNo. Substances2410Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlArthalgiaDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHerpes ZosterHyperkeratosisHypertensionHypoalbuminemiaHyponatremiaIncrease AminotransferasesIncrease in lipaseInfectionsNeurotoxicityNeutropeniaPruritusRashSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorCantu MACao XDiamond EGrobost VTazi AZinn DDiseaseErdheim-Chester-Krankheit / Langerhanszell-Histiozytose, Erst- und Zweitlinie, älter 16 Jahre, ECOG 0-3Erdheim-Chester-Krankheit und Langerhanszell-Histiozytose, BRAF V600–Mutation, Erstlinie, ECOG 0-2fortgeschrittene Langerhanszell-Histiozytose, WHO Lungen- Funktionsklasse Stadium II-IVLangerhanszell-Histiozytose des Erwachsenen, ErstlinientherapieLCH mit CD1a+ mit Knochenläsionen des ErwachsenenNeu diagnostizierte MS LCH oder ss-M LCH, Alter über 18rezidivierte oder refraktäre Langerhanszell-Histiozytose, Alter 0-72 JahreOriginAssistance Publique-Hopitaux de Paris, Hopital Saint-Louis, Centre National de Reference de l'Histiocytose Langerhansienne, Paris, FranceBaylor College of Medicine, Houston, Texas, United States of AmericaDepartment of Hematology, Peking, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Union Medical College, Beijing, ChinaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NYDepartment of Respiratory Medicine, Louis Pradel Hospital, Lyon, FranceMemorial Sloan Kettering Cancer Center, New York, New York, VE-BASKET StudyTexas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Houston, TXProtocols in Revision 8 protocols foundProtocols under revision.Cladribine 0.1, Langerhans Cell Histiocytosis (PID671 V1.0)Cobimetinib 60, Langerhans Cell Histiocytosis (PID1996 V1.0)Cytarabine 100, Langerhans Cell Histiocytosis (PID1666 V1.0)Hydroxyurea 500, Langerhans Cell Histiocytosis (PID1998 V1.0)Methotrexate 1000 / Cytarabine 100, Langerhans Cell Histiocytosis (PID1999 V1.2)Vemurafenib 960, Langerhans Cell Histiocytosis (PID1997 V1.0)Vinblastine 6 / Prednisolone (20/10), Langerhans Cell Histiocytosis, maintenance (PID959 V1.0)Vinblastine 6 / Prednisolone (20/10), Langerhans Cell Histiocytosis, induction (PID963 V1.0)
